Autoimmune encephalitis induced by sintilimab
10.3760/cma.j.cn114015-20240130-00071
- VernacularTitle:信迪利单抗致自身免疫性脑炎
- Author:
Quan WANG
1
;
Junwu ZHAO
;
Wei FANG
;
Jinfeng LI
Author Information
1. 山东大学附属威海市立医院药剂科，威海 264299
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Immune checkpoint inhibitors;
Neurological immune-related advert events;
Autoimmune encephalitis;
Sintilimab
- From:
Adverse Drug Reactions Journal
2025;27(5):315-317
- CountryChina
- Language:Chinese
-
Abstract:
A 61-year-old female patient was treated with sintilimab (200 mg by intravenous infusion on the first day, 21 days as a cycle) for lung adenocarcinoma and multiple lymph node metastases in the left hilum and mediastinum (10 cycles in total). Headache and dizziness in the patient occurred about 1 month after the last medication. Cerebrospinal fluid examination showed white blood cell count 14×10 6/L, total protein 799.8 mg/L, Pandy′s test (+), immunoglobulin G 70.8 mg/L, and glucose and chloride within the reference value range. The antibodies against N-methyl-D-aspartate receptor in cerebrospinal fluid and serum were all positive. The patient was diagnosed as having sintilimab-induced autoimmune encephalitis. After receiving methylprednisolone sodium succinate by intravenous infusion for 7 days, the patient′s headache and dizziness were alleviated. After that, the methylprednisolone sodium succinate was switched to oral prednisone acetate tablets. At a 2-month follow-up, no symptoms of headache or dizziness recurred in the patient.
